Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value
- PMID: 33315210
- PMCID: PMC7734451
- DOI: 10.1007/s41669-020-00243-6
Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value
Conflict of interest statement
Dr. Anderson has no conflicts of interest that are directly relevant to the content of this article. Dr. Baldwin served as site co-investigator for Gilead Sciences Remdesivir trials GS-US-540-5774 and GS-US-540-5773 and received no funding. Dr. Bach has received personal fees and non-financial support from the American Society for Health-System Pharmacists, United Rheumatology, Oppenheimer & Co, Kaiser Permanente Institute for Health Policy, the Congressional Budget Office, America’s Health Insurance Plans, and Geisinger; personal fees from WebMD, Defined Health, JMP Securities, Mercer, Foundation Medicine, Grail, Morgan Stanley, NYS Rheumatology Society, Cello Health, Anthem, Magellan Health, EQRx, Meyer Cancer Center of Weill Cornell Medicine, and the National Pharmaceutical Council; personal fees, non-financial support, and other support from Oncology Analytics; and grants from Kaiser Permanente and Arnold Ventures. All listed support was outside the submitted work.
Figures
Update of
-
Hospital length of stay for severe COVID-19: implications for Remdesivir's value.medRxiv [Preprint]. 2020 Aug 12:2020.08.10.20171637. doi: 10.1101/2020.08.10.20171637. medRxiv. 2020. Update in: Pharmacoecon Open. 2021 Mar;5(1):129-131. doi: 10.1007/s41669-020-00243-6. PMID: 32817960 Free PMC article. Updated. Preprint.
Similar articles
-
Hospital length of stay for severe COVID-19: implications for Remdesivir's value.medRxiv [Preprint]. 2020 Aug 12:2020.08.10.20171637. doi: 10.1101/2020.08.10.20171637. medRxiv. 2020. Update in: Pharmacoecon Open. 2021 Mar;5(1):129-131. doi: 10.1007/s41669-020-00243-6. PMID: 32817960 Free PMC article. Updated. Preprint.
-
Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01920-20. doi: 10.1128/AAC.01920-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32988821 Free PMC article. No abstract available.
-
A Study of Factors Affecting the Length of Hospital Stay of COVID-19 Patients by Cox-Proportional Hazard Model in a South Indian Tertiary Care Hospital.J Prim Care Community Health. 2021 Jan-Dec;12:21501327211000231. doi: 10.1177/21501327211000231. J Prim Care Community Health. 2021. PMID: 33729040 Free PMC article.
-
Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System.Pharmaceuticals (Basel). 2021 Jun 25;14(7):611. doi: 10.3390/ph14070611. Pharmaceuticals (Basel). 2021. PMID: 34202350 Free PMC article.
-
The impact of the COVID-19 pandemic on the length of stay following total hip and knee arthroplasty in a high volume elective orthopaedic unit.Bone Jt Open. 2021 Aug;2(8):655-660. doi: 10.1302/2633-1462.28.BJO-2021-0022.R1. Bone Jt Open. 2021. PMID: 34404226 Free PMC article.
Cited by
-
Empirical distributions of time intervals between COVID-19 cases and more severe outcomes in Scotland.PLoS One. 2023 Aug 16;18(8):e0287397. doi: 10.1371/journal.pone.0287397. eCollection 2023. PLoS One. 2023. PMID: 37585389 Free PMC article.
-
Remdesivir for the treatment of COVID-19.Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2. Cochrane Database Syst Rev. 2023. PMID: 36695483 Free PMC article. Review.
-
Interventions and outcomes of COVID-19 patients in a community hospital-A single center study comparing the first and second waves.PLoS One. 2022 Dec 16;17(12):e0279208. doi: 10.1371/journal.pone.0279208. eCollection 2022. PLoS One. 2022. PMID: 36525437 Free PMC article.
-
Discharge to post-acute care and other predictors of prolonged length of stay during the initial COVID-19 surge: a single site analysis.Int J Qual Health Care. 2023 Jan 2;35(1):mzac098. doi: 10.1093/intqhc/mzac098. Int J Qual Health Care. 2023. PMID: 36477564 Free PMC article.
-
Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19.Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221137848. doi: 10.1177/10760296221137848. Clin Appl Thromb Hemost. 2022. PMID: 36373759 Free PMC article.
References
-
- O'Day D. An open letter from Daniel O'Day, chairman and CEO, Gilead sciences. Forst City: Business Wirie; 2020.
-
- Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed 17 Sep 2020.
Grants and funding
LinkOut - more resources
Full Text Sources